Literature DB >> 12720596

Pharmacotherapy of painful diabetic neuropathy.

Richard Barbano1, Stephanie Hart-Gouleau, Janet Pennella-Vaughan, Robert H Dworkin.   

Abstract

The scope of this review is to describe the epidemiology, physiology, symptomatology, and treatment of diabetic painful neuropathy, which is a common complication of diabetes with significant morbidity. This article focuses on treatment options. Various clinical trials of several classes of medications (eg, antidepressants, anticonvulsants, and topical medications) and alternative treatments (eg, acupuncture, electrostimulation, magnets) are reviewed. Physicians have a large panel of medications that can be used effectively solely or in combination at their disposal. However, a number of these treatments have significant side effects, which are noted, that limit their use. As the understanding of the pathophysiologic mechanisms of diabetic neuropathy improves, new medications are under investigation, which are reviewed in this article. There is great hope that the future may hold treatments that would prevent nerve damage.

Entities:  

Mesh:

Year:  2003        PMID: 12720596     DOI: 10.1007/s11916-003-0070-9

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  72 in total

1.  Venlafaxine in treatment of severe painful peripheral diabetic neuropathy.

Authors:  F Lithner
Journal:  Diabetes Care       Date:  2000-11       Impact factor: 19.112

2.  Lamotrigine in the treatment of painful diabetic neuropathy.

Authors: 
Journal:  Eur J Neurol       Date:  1998-03       Impact factor: 6.089

3.  Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.

Authors:  M B Max; S A Lynch; J Muir; S E Shoaf; B Smoller; R Dubner
Journal:  N Engl J Med       Date:  1992-05-07       Impact factor: 91.245

4.  Nortriptyline-fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy.

Authors:  F J Gómez-Pérez; R Choza; J M Ríos; A Reza; E Huerta; C A Aguilar; J A Rull
Journal:  Arch Med Res       Date:  1996       Impact factor: 2.235

Review 5.  Pathophysiology and treatment of diabetic neuropathy.

Authors:  A Dejgaard
Journal:  Diabet Med       Date:  1998-02       Impact factor: 4.359

6.  Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study.

Authors:  A Devers; B S Galer
Journal:  Clin J Pain       Date:  2000-09       Impact factor: 3.442

7.  The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study.

Authors:  P J Dyck; K M Kratz; J L Karnes; W J Litchy; R Klein; J M Pach; D M Wilson; P C O'Brien; L J Melton; F J Service
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

8.  Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy.

Authors:  Phillip A Low; Tonette L Opfer-Gehrking; Peter J Dyck; William J Litchy; Peter C O'Brien
Journal:  Pain       Date:  1995-08       Impact factor: 6.961

9.  Association of pain relief with drug side effects in postherpetic neuralgia: a single-dose study of clonidine, codeine, ibuprofen, and placebo.

Authors:  M B Max; S C Schafer; M Culnane; R Dubner; R H Gracely
Journal:  Clin Pharmacol Ther       Date:  1988-04       Impact factor: 6.875

10.  Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial.

Authors:  J A Rull; R Quibrera; H González-Millán; O Lozano Castañeda
Journal:  Diabetologia       Date:  1969-08       Impact factor: 10.122

View more
  4 in total

Review 1.  Pharmacological treatment of diabetic neuropathic pain.

Authors:  Howard S Smith; Charles E Argoff
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

2.  Early alterations in myocardia and vessels of the diabetic rat heart: an FTIR microspectroscopic study.

Authors:  Neslihan Toyran; Peter Lasch; Dieter Naumann; Belma Turan; Feride Severcan
Journal:  Biochem J       Date:  2006-08-01       Impact factor: 3.857

3.  Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain.

Authors:  Thomas Forst; Terry Smith; Klemens Schütte; Paul Marcus; Andreas Pfützner
Journal:  Br J Clin Pharmacol       Date:  2007-03-28       Impact factor: 4.335

Review 4.  Use of natural compounds in the management of diabetic peripheral neuropathy.

Authors:  Maria Galuppo; Sabrina Giacoppo; Placido Bramanti; Emanuela Mazzon
Journal:  Molecules       Date:  2014-03-05       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.